This work reports the purification of new potent scorpion neuropeptide, named BotAF, by an activityguided screening approach. BotAF is a 64-residue long-chain peptide that shares very high similarity with the original b-like scorpion toxin group, in which several peptides have been characterized to be anti-nociceptive in rodents. BotAF administration to rodents does not produce any toxicity or motor impairment, including at high doses. In all models investigated, BotAF turned out to be an efficient peptide in abolishing acute and inflammatory (both somatic and visceral) pain in rodents. It performs with high potency compared to standard analgesics tested in the same conditions. The anti-nociceptive activity of BotAF depends on the route of injection: it is inactive when tested by i.c.v. or i.v. routes but gains in potency when pre-injected locally (in the same compartment than the irritant itself) or by i.t. root 40 to 60 min before pain induction, respectively. BotAF is not an AINS-like compound as it fails to reduce inflammatory edema. Also, it does not activate the opioidergic system as its activity is not affected by naloxone. BotAF does also not bind onto RyR and has low activity towards DRG ion channels (particularly TTX sensitive Na þ channels) and does not bind onto rat brain synaptosome receptors. In somatic and visceral pain models, BotAF dose-dependently inhibited lumbar spinal cord c-fos/c-jun mRNA up regulation. Altogether, our data favor a spinal or peripheral anti-nociceptive mode of action of BotAF.
Introduction
Animal venoms are reliable sources for drug discovery and implementation of new pharmaceutical tools (Attarde et al., 2016) . The richness and complexity in venom composition is the result of Darwinian selection forces onto several genes constituting families of coding toxins. As a result of this evolutionary pressure, the selected natural compounds act on an as diverse number of biological targets that include ion channels, G-protein coupled receptors, transporters and enzymes. Most often, these venom components bind with exquisite selectivity and potency on their receptors making venom-derived components highly attractive pharmacological tools and possible drug leads. The usefulness of venomous compounds as analgesics has been validated in several preclinical studies. This is the case of the following compounds: uconotoxin MVIIA (ziconotide) (Essack et al., 2012) , p-Theraphotoxin-Pc1a (PcTx1) (Escoubas et al., 2003) , APETx2 from a sea anemone species (Jensen et al., 2014) , and long neurotoxin OH-55 (hannalgesin) (Pu et al., 1995) . These analgesic compounds arise from different venom sources and species (conus, snake, sea anemone, spiders) and were discovered by using diverse screening strategies as well (target-based, toxin-based and activity-based). While many anti-pain compounds have been identified so far, ziconotide remains the only toxin-derived therapeutic for pain treatment that reached the clinics. This difficulty in converting preclinical leads into therapeutics may be the reflection of two major challenges: i) reaching proper potency and selectivity and ii) providing proper target accessibility and coverage. Part of these challenges may be met by further discovering novel compounds or simply by improving the potency, selectivity and delivery of known anti-pain toxins. As such, expanding the screening efforts to scorpion venom toxins may represent a promising approach. To date, most of the investigators interest has focused on long-chain insectotoxins based on the assumption that they should lack toxicity in mammals and on the well-documented analgesic potential of their targeted sodium channels in pain physiology. Indeed, this is the case for BmKIT2 (Guan et al., 2001) , BmkAS (Cui et al., 2010) , LqqIT2 (Martin-Eauclaire et al., 2010) and BmKAEP (Wang et al., 2011) . These compounds are purified by an in vivo screening approach of abundant venom compounds (or at least highly active compounds) checking for phenotypic or behavioral changes. Relevant compounds isolated this way are further investigated for identifying their molecular targets and for assessing their pharmacodynamics by in vitro approaches. While targetbased drug discovery allows for the identification of new molecular tools of interest in pharmacology, it may end up providing frustrating results in vivo because of the complexity of pain etiology, the challenges faced with the pharmacokinetics and the importance of the mode of administration, with or without adequate formulation. In contrast, compounds isolated against a rigorously defined in vivo pain model should deliver compounds that meet the criteria of preclinical evaluation, with yet uncertainties regarding the mode of action and the molecular target. The main advantage nevertheless remains that the compounds isolated through phenotypic assays will be more easily characterized with regard to the pharmacodynamics parameters (efficacy, potency, delivery…).
Herein, we used an activity-guided screening strategy to identify a venom compound from a Tunisian scorpion using an in vivo rodent pain model. We performed a double in vivo screening by assessing both toxicity and analgesia of the fractionated venom compounds. Next, we investigated some of its basic pharmacological properties in vivo by using standardized pain models and ruled out some possible anti-nociceptive molecular targets.
Materials and methods

Animals
All anti-nociceptive experiments were conducted on healthy adult male C57/BL6 mice (25e30 g) and adult female Whistar rats (180e220 g). For toxicity tests, male C57/BL6 mice (18e22 g) were used. Animals were housed at a density of 6 per cage and had free access to food and water in a quiet environment. The room was maintained at 21e23 C with a 12 h light/dark cycle. The experimenter was blind to the pharmacological treatment. All animal procedures were reviewed and approved by the Ethics Committee of the Pasteur Institute of Tunis according to the guidelines on the use of living animals in scientific investigations. All efforts were made to minimize both the suffering and number of animal used.
Purification procedure
120 ml of crude venom of the scorpion Buthus occitanus tunetanus (Bot) was obtained by electrical milking of field-collected scorpions at the Veterinarian Laboratory of the Institute Pasteur of Tunis. This crude venom of Bot was water extracted, then submitted to gel filtration chromatography on Sephadex G50 columns (2 Â K26/50, GE Healthcare, France) equilibrated with 0.1 M acetic acid. Five fractions (MI, MII, BotG50, III and VI) were resolved. Fractions MII and BotG50 were lyophilized, resuspended in water and further fractionated by a reversed-phase HPLC (HewlettePackard Series II 1100 liquid chromatography with diode array UV detection) equipped with a semi-preparative C8 column (10 mm Â 250 mm, 5 mm, Beckman Fullerton, USA). For this purpose, buffer A was 0.1% trifluoroacetic acid in water and buffer B was 0.1% trifluoroacetic acid (TFA) in acetonitrile. The column effluents were monitored at 280 and 214 nm. Peptide fractions were eluted at 1 mL/min in a linear gradient of buffer B in buffer A and at fixed 25 C temperature. Fraction F28, was loaded onto an analytical C18 reversed-phase HPLC column (10 mm Â 250 mm, 5 mm, Beckman Fullerton, USA) using a linear gradient of buffer B in buffer A allowing the isolation of BotAF. Protein concentration was measured by amino-acid analysis.
Mass spectrometry
Samples were analyzed on a Voyager-DETM PRO MALDIeTOF (matrix-assisted laser-desorption ionizationetime-of-flight) Workstation mass spectrometer (Perceptive Biosystems, USA). The peptide was dissolved in 30% acetonitrile with 0.3% TFA to obtain a concentration of 1e10 pmol/mL. The matrix was prepared as follows: a-cyanohydroxycinnamic acid was dissolved in 50% acetonitrile in 0.3% TFA/H 2 O to obtain a saturated solution at 10 mg/mL. A 0.5 mL of peptide solution was then mixed with 0.5 mL of matrix solution and placed on the sample plate, and the mixture was allowed to dry. Mass spectra were recorded in reflectron mode after external calibration with suitable standards and were analyzed using the GRAMS/386 software (Galactic Industries Corporation).
Reduction and alkylation of peptide
Five nanomoles of BotAF was dissolved in 40 mL of alkylation buffer (6 M guanidine HCl, 0.5 M Tris/HCl, 2 mM EDTA, pH 7.5) containing 1.4 mmol dithiothreitol (DTT). After 1 h of reduction at 37 C, 9 mmol of 4-vinylpyridine (4-VP) was added for alkylation.
The S-alkylated BotAF (SA-BotAF) was then desalted by dialyze against 10% acetic acid at 4 C overnight using Spectra/Por 6 membrane tubing with a 4000 MW cut-off (Spectrum Laboratories Inc., USA). The dialyzed product was then subjected to SDS-PAGE on a 15% gel and then revealed by Coomassie Blue staining.
In-gel digestion of alkylated BotAF by trypsin and S. aureus V-8 protease
The in-gel digestion of SA-BotAF was performed as previously described (Jen€ o Paul et al., 1995) . Briefly, SDS-PAGE gel protein bands were excised after Coomassie Blue distaining, then washed with 40% n-propanol followed by 0.2 M NH 4 HCO 3 /50% acetonitrile, and finally dried in Speed Vac. Gel pieces were rehydrated in 100 mL of 100 mM NH 4 C0 3 pH 7.8 containing 1 mg trypsin or S. aureus V8 protease. After 24 h of digestion at 37 C, peptide fragments were extracted three times from the gel slices with three consecutive treatments: first, 200 mL of 0.1% TFA, 0.01% Tween 20; second, 100 mL of 1% TFA, 0.01% Tween 20; and third, 100 mL of 0.1% TFA, 50% acetonitrile, 0.01% Tween20 (Eckerskorn and Lottspeich, 1990) . Enzymatic digests were separated by high-performance liquid chromatography on an analytical C18 reverse phase HPLC column.
Amino acid sequencing and sequence analyses
The amino acid sequences of the N-terminal fragment and of the peptides derived from proteolytic digests of SA-BotAF were determined by an automatic liquid-phase protein sequencer (model 476A, Applied Biosystems, USA) using a standard Edman protein degradation procedure (Edman and Begg, 1967) . Search for proteins homologous to BotAF was performed using the NCBI BLAST database search program implemented at the web site (http://www. ncbi.nlm.nih.gov/). The amino acid sequence of BotAF was aligned with other toxins using Clustal W (Thompson et al., 1994) running in BioEdit version 7.2.6 (Hall, 1999) .
Cloning of BotAF isoforms
Total RNA were extracted from homogenized Bot scorpion telsons, containing venomous glands, using the RNAgents kit from Promega (Madison, WI, USA). 5 Bot scorpions were used for this purpose. Single stranded cDNA was obtained by reversedtranscription using an universal oligo(dT)-containing adapter primer (5 0 -GGCCACGCGTCGACTAGTAC(dT) 17 -3 0 , Proligo). The following reaction mixture: 12 mL of DEPC (diethylpyrocarbonate)-treated water containing 0.1 mg of primer and 1 mg of total venom gland RNA, 2 mL of 0.1 M DTT, 1 mL of RNAsin (ribonuclease inhibitor at 40 units/mL from Promega), 1 mL of dNTP (10 mM each, Promega) and 200 units of M-MLV RT (Moloney murine leukaemia virus reverse transcriptase). The final volume was adjusted to 20 mL, and the reaction mixture was incubated at 37 C for 1 h, followed by 10 min at 95 C to inactivate the enzyme. At the end of the reaction, RNAse H was added to degrade mRNA.
Next, cDNA sequence encoding BotAF analogues were amplified by PCR using venom gland cDNA as template and the following primers: a forward primer corresponding to a degenerated sequence
derived from the N-terminal peptide sequence of BotAF and also based on the cDNA sequence homology of three homologous peptides of BotAF (BmKAS, BmKAS1 and BotIT2), and a reverse primer (5 0 -GGC-CAC-GCG-TCG-ACT-AGT-AC-3 0 ), corresponding to the universal amplification primer used for cDNA synthesis. The PCR protocol included an initial denaturizing step at 95 C for 2 min followed by 35 cycles of denaturation (30 s at 94 C), annealing (30 s at 52 C) and extension (30 s at 72 C), and a final extension for 7 min at 72 C.
The amplified fragments were separated on 1% agarose gel electrophoresis. Desired bands were excised under UV-light and purified using the Gel Extraction Kit (QIAGEN) and were cloned into pGEM-T vector (Promega). Positive recombinant clones were confirmed by PCR-amplification and sequencing.
Toxicity test and rotarod test
BotAF was tested for in vivo toxicity on 20 ± 2 g male mice C57/ BL6 by intracerebroventricular (i.c.v.) injection of 7 mL of saline solution containing increasing amounts of the peptides. Six mice were used for each concentration. Behavioral parameters considered as signs of toxicity were: tremors, convulsions, paralysis, upward tail and fur, abnormal gait and posture (Clot-Faybesse et al., 2001; Galeotti et al., 2003) . Mortality was assessed 48 h after i.c.v. administration.
Accelerating rotarod test (Jones and Roberts, 1968) was assessed prior to pain behaviors study to further check if there is any motor impairment due to BotAF injection. The rotarod apparatus (Ugo Basile Biological Research Apparatus, Varese, Italy) is used as described (Plummer et al., 1991) . Briefly, male C57/BL6 mice (18e22 g) were placed on the rod when it was rotating at a speed of 2.5 rpm. After 10 set, the timer was started and the speed of the rod was increased (2.5e25 rpm over 5 min). Four BotAF-treated groups (6 mice per group) were tested: (1, 2 mg/kg) i.p. and (0.2, 0.5 mg/kg) i.t.. The drop latency for each tested animal groups was recorded before, 30 min, and 60 min after treatments. Evaluation of BotAF action on motor impairment was assessed by comparing, for each group, the drop latency recorded before and 30 min or 60 min after treatment.
Intrathecal injection
Intrathecal administration was done by a direct injection on conscious rat and mice as described previously (Mestre et al., 1994) . Briefly, the injections were performed by a 25-Ga Â 1 00 needle, connected to a 25-1xL Hamilton syringe, into the tissues between the dorsal aspects of L5 and L6, perpendicular to the vertebral column. This site was selected so that the injection was restricted to the region where the spinal cord ends and the cauda equina begins in order to reduce the possibility of spinal damage and increase the intervertebral accessibility. The syringe was held in position for a few seconds and progressively removed to avoid any outflow of the drug.
Pain models
All injected drugs were dissolved in saline. Volumes for mice injection were: 7 mL by i.c.v., 150 mL intraperitoneally (i.p.), 15 mL by intrathecal route (i.t.) and 50 mL by intraplantar (i.pl.). Each animal was tested only once and sacrificed thereafter. Several pain models were used: the hot-plate test, the writhing test, the tail flick test and the formalin test, as briefly described hereunder.
The writhing test consists of an i.p. injection of acetic acid (0.6%, 7.5 mg kg À1 ) to mice pretreated at different time before with the compounds of interest. Results are presented as inhibition percent of the contortion numbers that occur during 30 min following the injection of acetic acid (Collier et al., 1968) . For the hot-plate test, mice are placed into a glass cylinder (14 cm diameter and 20 cm height) on a hot-plate adjusted to 55 C (hot-plate analgesia meter, Harvard Apparatus, USA). The latency of the hind paw licking was used as an index of pain reaction. A 60 s cut-off was used to preserve the physical integrity of the animal.
Concerning the tail flick test, the apparatus consists of a shuttercontrolled lamp as a heat source (tail flick analgesia meter, Harvard Apparatus, USA). The test was performed as described previously (D'Amour and Smith, 1941) . Briefly, the tail of the mice was marked at a distance of 2 cm from the apex and was placed under the heat source. The time taken by the treated animal to flick its tail was recorded. A cut-off of 60 s was used to respect animal integrity.
For the formalin test, 50 mL of 5% formalin was administered i.pl.
into the left hind paw. Each rat was placed individually in a plexiglass test box for at least 30 min to adapt to the new environment before administration of the chemical agents. Nociceptive behaviors were determined by counting the time spent in liking and flinching the injected hind-paw over consecutive periods of 5 min during 1 h following formalin injection. Data collected between 0 and 10 min post-formalin injection compose phase 1, and data collected between 15 and 60 min post-formalin injection represent phase 2 (Abbott et al., 1995) .
Volume changes of rat hind paw inflammation
Paw edema was induced by injection of 100 mL of carrageenan (final concentration 15 mg/kg) into the rat left hind paw. Edema was followed by measuring changes in paw volumes using a plethysmometer (Ugo Basile, Italy) at various times (0, 1, 2, 3, 4 and 5 h). Before carrageenan treatment, the rats receive in the same paw an injection of vehicle, dexamethasone (100 mL, 1 h before) or BotAF (20 min before) at concentrations as indicated in the text. The increase in paw volume is considered as an index of inflammation intensity (Di ROSA and Sorrentino, 1968) . To measure paw volume fluctuation, the injected hind paw was immersed into a water cell filled with a solution of 0.04e0.05% NaCl according to manufacturer's instructions, and the volume of spillage considered as the volume of hind paw.
Analyses of c-fos/c-jun expression profiles
Lumbar spinal cords were quickly removed by syringe aspiration after decapitation of mice (n ¼ 3 per group), 3 h after drugs or saline (control) administration and put immediately in nitrogen before mRNA extraction. Total RNA were prepared from mouse spinal cords using Macherey-Nagel Kit (NucleoSpin RNA II) and were converted in cDNA using First Strand cDNA Synthesis kit (GE Healthcare). Transcripts from c-fos or c-jun were quantified using TaqMan probes obtained from Applied Biosystems (Foster City, Ca). Calculations were performed using mRNA c-fos or c-jun/mRNA glyceraldehyde 3 phosphate dehydrogenase (GAPDH) ratio. GAPDH was chosen as a house keeping gene.
Electrophysiological study
Adult rat DRG neurons were isolated and cultured according to the method described by Herzog et al. (2003) . Briefly, rats were anesthetized and decapitated. Cells were treated with collagenase (1 mg/mL) and papain (1 mg/mL), dissociated in DMEM supplemented with 10% fetal bovine serum, and plated on glass coverslips coated with poly-L-ornithine and laminin. Cultures were maintained at 37 C in a 5% CO 2 incubator, and media was changed every 2 days during experimental incubation periods. DRG neurons express both tetrodotoxin-sensitive (TTX-S) and TTX-resistant (TTX-R) sodium channels.
Whole-cell recordings were performed on DRG neurons. Membrane currents were measured with pipettes (2e5 MU) pulled from glass capillary tubes and connected to an EPC-9 amplifier operating Pulse:Pulsefit software (HEKA elektronik, Germany). The pipette solution was composed of (in mM): CsCl 120, TEACl 20, Na 2 ATP 5, EGTA 10, HEPES 10, MgCl 2 2.5, Na 2 GTP 0.4. The pH of the solution was adjusted to 7.3 with CsOH. The external solution was composed of (in mM): NaCl 140, KCl 5, CaCl 2 2.5, MgCl 2 1, HEPES 10, D-glucose 10. The solution was adjusted to pH 7.3e7.4 with NaOH. Ag-AgCl saline bridge was used for the reference electrode. The peak sodium currents were selected out and normalized by their relative amplitude to control.
Iodination of BotAF and synaptosome preparation
BotAF was iodinated by the lactoperoxidase method of [ 125 I] iodide oxidation according to Rochat et al. (1970) . The specific radioactivity was found to be 200 Ci/mmol. The native BotAF was tested for its ability to displace [ 125 I]-BotAF from the binding site of synaptosome P2 preparations (Gray and Whittaker, 1962) . Synaptosomes (3.3 mg/mL) were incubated in a medium containing 130 mM choline chloride, 5.4 mM KCl, 5.5 mM glucose, 0.25% bovine serum albumin, 50 mM HEPES, pH 6.5; 0.2 nM [ 125 I]-BotAF and increasing concentrations of BotAF were then added. After 30 min at 37 C, the synaptosomes were centrifuged (11,000 Â g for 1 min), the residual pellets were washed twice with the same medium and the bound radioactivity measured. The values are means of duplicate determination.
Effect of BotAF on [ 3 H]-ryanodine binding to SR vesicles
SR vesicles from rabbit muscles were prepared as described previously in Marty et al. (2000) by filtration through Whatmann GF/B glass filters followed by three washes with 5 mL of ice-cold washing buffer composed of 150 mM NaCl, 20 mM HEPES, pH 7.4. Filters were then soaked overnight in 10 mL scintillation cocktail (Cybscint, ICN) and bound radioactivity determined by scintillation spectrometry.
Statistical analyses
Statistics and determination of ED 50 values were done using GraphPad Prism ® (version 4.02, GraphPad, San Diego, CA). The results are expressed as mean ± S.E.M with the exception of the ED 50 value (the dose of compound that produces 50% of the effect relative to the control value) value, which was reported as the geometric mean accompanied by respective 95% confidence limits.
ED 50 values were determined by non-linear regression analysis using a sigmoid dose-response equation. Ratios were considered significant if the confidence interval did not overlap. N ¼ 6 animals for each dose of compound used in all tests. The level of significance was set at 5% (P < .05), and denoted by one *.
Results
Purification of a new analgesic peptide from Bot venom
120 mL of scorpion Bot venom was water extracted, centrifuged and the supernatant was fractionated using gel filtration chromatography on Sephadex G50 . Five fractions were resolved: MI, MII, BotG50, III and IV (Fig. 1A ). Fractions were lyophilized and resuspended in water at 0.3 mg/mL. Toxicity assays were performed on mice by i.c.v. injection of 0.1 mg/kg or by i.p. administration of 5 mg/kg of each fraction. At this concentration, fractions MI, MII, III and IV were non-toxic in opposition to BotG50wich was lethal. These fractions were tested for their ability to induce analgesia in mice using the writhing test. Fractions were injected i.p. at 5 mg/kg and evaluated for analgesia 1 h later. As shown, only fraction MII displayed a significant decrease in abdominal writhes (Fig. 1B) . Next, the MII fraction was further fractionated by reversed-phase C8 semi-preparative HPLC (Fig. 1C) . Among the collected fractions, only fraction F10 i.p. administrated at 5 mg/kg (arrow in Fig. 1C ) displayed analgesic effect using the writhing test (Fig. 1D) . At this stage, two factors prevented further characterization of the active peptide: (i) a poorly resolved peak as determined by C8 HPLC and (ii) the fact that the F10 fraction is only a minor component of the MII fraction. To solve this issue, we next determined whether a fraction similar to F10 in terms of elution profile may be present also in the BotG50 fraction, which seemed possible because of the partial overlap in MII and BotG50 fractions (Fig. 1A) . As shown by the HPLC profile of the BotG50 fraction, a fraction that presents similar characteristics to F10 is also present in the BotG50 fraction, but in greater amounts and with better resolution (Fig. 1E) . In BotG50 C8 chromatographic profile F10 appears as a pool of smaller fractions defined as FI, F28, FIII, FIV and FV, that were all further evaluated for their toxicity in mice. None of these smaller fractions were toxic up to 0.1 mg/kg by i.c.v. and 5 mg/kg by i.p. route which permitted their evaluation for the writhing test pain model. Of all these fractions tested, only F28 has the ability to attenuate abdominal contortions in mice upon i.p. injection at 2 mg/kg (Fig. 1F) . When further resolved on an analytical reversedphase C18 column, F28 eluates as a single well-resolved peak at a fixed retention time of 14 min encompassing a molecule that we termed BotAF for Buthus occitanus tunetanus Analgesic Factor (Fig. 1G) . In this elution profile, other minor contaminants were also present. Intraperitoneal pretreatment of mice with 2 mg/kg of purified BotAF was sufficient to attenuate up to 85% of abdominal cramps, whereas injection, in same experimental conditions, of a collected pool of the contaminants, had no effect (Fig. 1H ).
According to crude estimations, BotAF represents less than 1% of peptide components of the BotG50 fraction and less than 0.5% of total venom extract. BotAF has an experimental mass (MþH þ ) of 7419.19 Da as determined by MALDI-TOF mass spectrometry (Fig. 1I) . This result indicates that BotAF belongs to a long-chain class of scorpion toxins. Amino acid analyses indicate that BotAF is pure at 98%. 
Amino acid sequence of BotAF and sequence homology
To determine the amino acid sequence of BotAF, 5 nmol of peptide was first reduced by 1.4 mmol DTT. The reduced peptide was then alkylated with 4-VP (to yield reduced-alkylated BotAF (RABotAF)), and subjected to direct Edman degradation. A partial sequence was obtained from the N-terminus up to amino acid position 30 ( Fig. 2A) . To get additional sequence data, RA-BotAF was also separated by SDS-PAGE and gel-digested with either trypsin or S. aureus V8 protease, as described in Materials & Methods. The proteolytic peptide fragments from both digests were extracted from gel slices and separated by C18 analytic HPLC (Fig. 2B) . As shown, trypsin digestion results into at least 14 major peptide fragments (left panel), whereas V8 protease digest yielded at least 13 fragments (right panel). Fragments T-2, T-4 and T-8 from trypsin digest and fragment V8-6 from V8 protease digest were purified and sequenced by Edman degradation. The resulting sequences are provided in Fig. 2A . Sequence overlapping analysis of the N-term sequence of RA-BotAF, T-4 and T-2 was used to determine the correct order in the final sequence. T-8 was 7 residues long and seems to prolong T-4 sequence to the C-terminus according to sequence homology with BmKAS and BmKAS1 (Fig. 3) . The V8-6 fragment overlaps and prolongs the T-8 sequence and should complete the sequence of BotAF according to the molecular mass obtained. In fact the theoretical mass of reduced BotAF is 7427.37 Da, which should correspond to a theoretical mass of 7419.37 for folded/oxidized BotAF, a value identical to the experimental mass obtained. BotAF is therefore a peptide of 64 amino acids, presumably containing 4 disulfide bridges.
To search for BotAF-like sequences, we therefore undertook the cloning and sequencing of cDNAs coding for BotAF-like toxins. The mRNA was extracted from Bot venomous glands and cDNA was synthesized by reverse transcription. Resulting cDNAs were PCRamplified with a couple of predesigned primers: a forward primer designed on the basis of the N-terminal amino acid sequence of BotAF and the cDNA sequence of three homologous toxins, BmKAS, BmKAS1 and BotIT2, and a reverse oligo dT sequence. Amplified PCR products were subcloned into pGEM-T vector and sequenced. Several cDNA sequences were obtained coding for b-like long-chain toxins, but one sequence matched more closely what could be expected for the cDNA sequence of BotAF (Fig. 2C) . It encodes the BotAF2 pro-toxin. The open reading frame for the BotAF2 pro-toxin is 196 bps-long ending with a TGA stop codon. A polyadenylation signal is located 157 bps from the termination codon. Translation of this sequence yields BotAF2 (Fig. 2D) . BotAF2 also contains 64 amino acids and should fold according to the same pattern as BotAF. The predicted molecular mass of BotAF2 is 7391.33.
BotAF and BotAF2 are two new members of the b-like longchain scorpion toxins
A blast search was performed to identify toxins sharing sequence homology with BotAF and BotAF2 sequences. Interestingly, there is a high homology (>70%) with b-like scorpion toxins (BmKAS, BmKAS-1, BmP09, Lqhb1 and AaHIT4). Multi sequence alignment for BotAF using ClustalW software was performed (Fig. 3A. ). Sequence identities ranged from 70% (AaHIT4) to 78% (BmKAS). ClustalW alignments were also performed between BotAF and depressant anti-insect toxins with characterized analgesic activity (except for BotIT2), and results presented in Fig. 3B show that BotAF is sharing also high identity with this group, albeit lower (between 43 and 50%).
Toxicity and rotarod tests
No mortality was noticed 24 h after treatment of mice by increasing doses of BotAF by i.c.v. route (up to 0.5 mmol/kg) or by i.p. route (up to 1 mmol/kg). Since no external signs of toxicity were observed, we conclude that BotAF exhibits no toxicity in vivo (see Materials & Methods section).
The Rotarod experiments demonstrate that BotAF at antinociceptive doses has no effect on motor function. In fact, as shown in Fig. 4A , no significant difference is seen between the drop latency time in mice groups treated with BotAF (0.5, 1 mmol/kg) i.p. or (0.2, 0.5 mmol/kg) i.t. versus control groups (treated with vehicle in the same conditions).
Anti-nociceptive effect of BotAF in writhing and hot-plate tests
Using the anti-nociceptive writhing test, BotAF has no effect when injected by i.c.v. or i.v. routes up to 0.3 mg/kg (data not shown). In contrast, a significant reduction in acetic acid-induced contortions was observed if BotAF is administered by i.p. route (Fig. 4B ). This effect is dose-dependent and reaches maximum at 5 mg/kg. Optimal anti-nociception is observed if BotAF is injected i.p. 60 min before the test, but good anti-nociception (up to 50%) is still observed 90 min after BotAF administration. A dose-response curve was constructed and compared to the effect of b-endorphine (Fig. 4C) . The ED 50 of BotAF is 154.2 nmol/kg (i.p., 60 min before test), while that of b-endorphine is 358.4 nmol/kg (i.p., 40 min before test). These results indicate that BotAF is a 2.3-fold more potent anti-nociceptive compound than b-endorphine for viscero-somatic pain by i.p. administration.
Next, we evaluated the efficacy of BotAF on preventing acute somatic nociception by using the hot-plate test (Fig. 4D) . BotAF dose-dependently attenuates somatic pain by prolonging the paw withdrawal latency of C57/BL6 mice to hot plate stimuli. This antinociceptive activity is dependent on the time between the treatment and the nociceptive activity test. The maximum effect occurs 60 min after i.p. injection. In comparison, b-endorphine reaches maximal effect 30 min after i.p. injection, but the effect is prolonged for more than 1 h after this peak. Dose-response curves illustrate an ED 50 of 788.4 nmol/kg (i.p., 60 min before test) for BotAF, while that of b-endorphine is 1995 nmol/kg (i.p., 40 min before test). Here, again BotAF is 2.5-fold more efficient than b-endorphine upon i.p.
injection. In this test also BotAF has no effect by i.c.v. or i.v. injections.
Effect of BotAF on tail-flick test behavior
The i.p. injection of BotAF significantly and dose-dependently increases the tail withdrawal latency (Fig. 5A) . The maximal antinociceptive effect is obtained, like in the hot-plate test, at 60 min after treatment and anti-nociception is still significant up to 120 min after peptide injection. Evaluation of dose-response curves provides ED 50 of 517.3 nmol/kg for BotAF (i.p., 60 min before test), while that of b-endorphine is 2401 nmol/kg (i.p., 40 min before test) (Fig. 5B) . BotAF remains therefore more potent than bendorphine, with about 4-fold difference this time. These data indicate that there are not many differences in efficacy of BotAF with regard to the somatic pain challenged if injected i.p.
The analgesic activity was further investigated in this model by i.t. injection. Again, a maximal effect of BotAF on tail withdrawal latency was observed 60 min after its i.t. injection (Fig. 5C ). This effect occurred at lower concentrations than upon i.p. injections ( Fig. 5C and D) , and was more transient in duration. Evaluation of the dose-dependence of this effect yields an ED 50 of 57.38 hmol/kg (60 min before test), which is thus about 9-fold more potent than by i.p. administration (Fig. 5D) .
BotAF antinociceptive effect by i.pl. injection in the formalin test
The intraplantar injection of 2.5% formalin into the left hind paw produces a consistent flinch and lifting/licking response in rat. The time course curves of these counted behaviors is biphasic in time (Fig. 6A) , comprising two phases: phase 1, lasting 0e5 min and corresponding to acute inflammatory pain and phase 2, lasting 10e60 min and corresponding to chronic inflammatory pain. As shown in Fig. 6A , BotAF (0.23 mmol/kg or 0.47 mmol/kg) intraplantary injected 30 min before formalin, significantly attenuates pain behaviors of both phases 1 and 2 as compared to control group. Average flinching scores of BotAF during phase 1 and phase 2 are shown in Fig. 6A and compared to the scores obtained for profenid (12 mmol/kg, i.pl. 30 min before test) and for morphine sulfate (0.6 mmol/kg, i.pl. 30 min before test). As expected, profenid produces significant anti-nociception only on the inflammatory phase, while morphine sulfate is active on both phases. Dose-response curves of all three compounds, administrated by the intraplantar root (i.pl.), are shown on both phases except for profenid (Fig. 6B) . As shown, the ED 50 for BotAF are 225.7 nmol/kg (phase 1) and 204.9 nmol/kg (phase 2), while ED 50 for morphine sulfate are 552.2 nmol/kg (phase 1) and 442.9 nmol/kg (phase 2). These data suggest that BotAF, injected locally, acts as well on phase 1 than on phase 2, similarly to morphine sulfate. On average, potency ratios show that BotAF is more efficient by 2 fold than morphine sulfate.
Modulation of c-fos/c-jun expression by BotAF in visceral and somatic pain conditions
As shown, in Fig. 7 , the i.p. injection of acetic acid, produces a drastic increase in c-fos and c-jun mRNA levels 2 h after viscerosomatic pain induction. The i.t. administration of BotAF dosedependently inhibits this mRNA expression increase. This inhibition is complete for c-fos and c-jun. Similarly, using a somatic inflammatory pain model (i.pl. formalin injection 2 h before assessing mRNA levels), BotAF pretreatment (i.p., 15 min before formalin injection) dose-dependently prevents c-fos and c-jun mRNA up-regulations ( Fig. 7C and D) . In this model also, the inhibition of mRNA level increase is complete for both c-fos and c-jun.
Furthermore result in Fig. 7C and D shows that BotAF (0.4 mmol/kg, i.p.) when injected alone (with no other drug) does not induce any significant up-regulation of c-fos and c-jun mRNA level as compared to non-treated control group.
Pharmacology of BotAF anti-nociceptive activity
The pharmacological activity of BotAF was investigated on voltage-gated Na þ currents in rat DRG neurons maintained in primary cultures. The membrane potential of rat DRG neurons was held at À80 mV, which was near the resting membrane potential. Whole-cell path-clamp recording found that about only 10% of peak total sodium currents of rat DRG neurons could be significantly inhibited by 1 mM of BotAF (Fig. 8A ). This inhibition could be largely recovered upon washout of BotAF. We also assessed the effect of 1 mM BotAF on the fraction of TTX-resistant currents and the results show that BotAF significantly inhibited (about 20%) TTX-R currents (data not shown). It is therefore concluded that BotAF is not a good Na þ channel blocker and that its anti-nociceptive effect is unlikely to involve block of Na þ channels.
To measure the interactions of BotAF with CNS ion channels, competition binding assays to rat brain synaptosomes were performed with a fixed concentration of [ 125 I]-BotAF and increasing concentrations of BotAF. The results show that BotAF, with and IC 50 of 2.2 mM, has a low affinity for rat brain synaptosomes receptors (Fig. 8B) . Similarly, BotAF activity was tested on ryanodine receptors. As shown, 1 mM BotAF has no effect on [ 3 H]-ryanodine binding onto SR vesicles (Fig. 8C) , indicating that ryanodine receptors are also not good targets for BotAF.
The involvement of the opioid endogenous system in the analgesic activity of BotAF was also assessed in the tail flick model. We studied its possible attenuation by the opioid antagonist naloxone. As shown in Fig. 9A , naloxone pre-treatment does not affect the anti-nociceptive activity of BotAF, assessed in the tail flick model, indicating that this peptide does not act on opioid receptors for its analgesic effect.
Finally, the anti-inflammatory activity of BotAF was determined in vivo by paw edema volume assessment. Dexamethasone (a wellknown AINS drug) or BotAF were injected intraplantary 1 h before paw edema induction by carrageenan injection. As shown in Fig. 9B , only dexamethasone potently inhibited paw inflammation, while
BotAF injected intraplantary, up to 1.8 mmol/kg, was ineffective in reducing Paw edema volume. 
Discussion
Here, we identified a novel toxin, BotAF, that produces potent analgesic effects in rodents. BotAF was purified from the venom of Bot using an activity-guided screening strategy. This consisted in isolating a compound from Bot venom fractions by assessing its anti-nociceptive effect in vivo together with confirming the lack of toxicity of the active compound. This strategy requires several conditions to be successful: (i) an important quantity of venom provided by unique facilities, (ii) a non-toxic peptide, (ii) a highly active or sufficiently abundant compound and, (iii) a reliable (or several) pain model(s). In this chosen screening approach, the writhing test appears adequate since it is highly sensitive test that lacks selectivity allowing the identification of a larger number of molecules regardless of the pharmacological target involved in nociception. In addition, to satisfy the exigence of the screening approach, we deliberately focused on the G-50 venom fractions that are devoid of lethality upon i.c.v. or i.p. injection into mice. As most scorpion venom compounds are toxic, this approach should promote the discovery of original new active compounds. In agreement with this expectation, we indeed found BotAF to represent a minor compound with less than 1% of the venom content. This finding also illustrates to which extent the in vivo screening is valid.
The BotAF sequence was determined by direct sequencing. The whole sequence of BotAF consist of 63 amino-acids and the peptide has a MW of about 7419 Da. Homology alignments demonstrate that BotAF structurally belongs to a family of recently characterized toxins, termed b-like scorpion toxins (Gordon et al., 2003) . This family contains so far four members, all from the Buthidae family of scorpions: BmKAS, BmKAS1 (Lan et al., 1999) , AaHIT4 (Loret et al., 1994) and Lqhb1 (Gordon et al., 2003) . These toxins have a minimum of 70% sequence identity and vary in length from 63 to 66 amino acids. . Of relevance to our findings, two members of this family of toxins, BmKAS and BmKAS1, have been reported as efficient analgesics by several tests (Chen and Ji, 2002; Chen et al., 2006; Shao et al., 2008 ). BotAF has also a level of sequence identity (between 43 and 50%) with antiinsect depressant toxins such as BmKAEP (an analgesic and antiepileptic toxin). Several other members of the anti-insect depressant toxin family have analgesic properties as well (Guan et al., 2001; Bai et al., 2007) . We reveal also very limited sequence identities with members of the b-toxin family, known for their toxicity in vivo. Beside its analgesic potential, the so-called beta-like toxin group shows several original features compared to other scorpions groups as it is composed by a restricted set of members sharing high sequence similarities but also peculiar and diverse pharmacological profiles. Thus, BotAF constitutes by itself a very promising lead for future structure-function studies and for understanding the evolution of scorpion's toxins.
As BotAF seems to have a promising pharmacological profile, it seemed of interest to search for analogues within the same venom as alternative splicing of genes coding for toxins is a frequently used strategy to enrich the repertoire of active compounds. The success of this approach was exemplified herein by molecular biology as toxin cloning from Bot venomous glands provided the sequence of a new BotAF isoform, termed herein BotAF2. BotAF2 differs from BotAF by only three amino acid residues and is therefore likely to possess the same anti-nociceptive effect than BotAF itself. Nevertheless, this assumption can be proven true only when the full synthesis of BotAF2 will be performed chemically or through recombinant means. For the time being, we did not find out in which fraction of the venom BotAF2 was present, possibly also because it also represents a minor component of the venom.
Our work also attempted to deepen the in vivo activity of BotAF. Toxicity of the molecule was investigated by means of lethality assessment after 48 h and by direct observation of any mice behavioral change that could reflect a form of intoxication summarized in bibliographic data in which these symptoms were well characterized (Ozkan et al., 2007; Pipelzadeh et al., 2015) . Besides toxicity, it was also important to assess animal motor response in BotAF administration condition. Many pain models used for investigating nociception in conscious laboratory animals rely upon an observable motor response and the analgesic potential is evaluated on the basis of changes in the latency of motor responses following nociceptive stimulation (heat, acetic acid…). Interpretation of an increase in response latency as evidence that analgesia takes place is invalid if the putative analgesic factor interferes with motor function (Warren and Lson, 1982) . Such confounding motor effects can be assessed in many ways, including the rotarod test. Thus, we used this particular test to measure whether or not BotAF affects the motor coordination of rodents over the time periods and experimental conditions used in revealing its antinociceptive activity. Using this procedure, we confirmed that behavioral changes in mice challenged with BotAF was not due to impairment of the normal motor function but to its anti-nociceptive action.
Next, the potency and specificity of the analgesic activity of BotAF was analyzed, first in vivo by assessment of animal behavioral changes in several pain models, and, secondly, in vitro by assessing nociceptors activation. We started with acute pain models: writhing test (model designed for visceral pain), hot plate test and tail flick test (somatic pain). In those models, BotAF shows a potent preemptive analgesia (with an optimal activity obtained when injected 1 h before pain induction) as confirmed by ED 50 values compared to b-endorphine as a reference analgesic drug. In addition, BotAF analgesic activity was further investigated on an inflammatory pain model: the formalin test. The data demonstrate that BotAF is efficient towards abolishing inflammatory pain with high potency compared to profenid and morphine-sulfate. The interesting potent analgesia of BotAF in all tested models is particularly informative when considering the different pain syndrome that they represent. In fact, such lack of specificity for a particular pain type (visceral/somatic/acute/inflammatory…) is in favor of an action of BotAF on the nerve conduction and/or the central transmission of pain information rather than on the pain induction processes themselves (stimulus transduction). In this context, it is worth reminding that the analgesic efficacy of other reported venom peptides is dependent on their mode of administration. This, in turn, has often limited their clinical use (see for instance Prialt restricted to i.t. injection (Rauck et al., 2009) ), or restrained their usage to a preclinical level. Concerning BotAF, it was ineffective by the i.c.v. or i.v. roots. Conversely, the compound was highly effective when administrated by the i.t. root regardless of the pain etiology. It should therefore face similar challenges for the clinical applications as Prial. However, contrary to the later, BotAF shows a gain in potency in the formalin test when injected intrapodally which should facilitate to some extent its clinical application.
The analgesic activity of BotAF was further evaluated in vitro by quantifying medullar c-fos and c-jun mRNA expression. Painful visceral (acetic acid in peritonea) or somatic stimuli (intrapodal formalin injection) leads to a rapid and transient induction of the expression of the immediate early genes c-fos and c-jun in lumbar spinal cord (Barr et al., 2003; Bianchi et al., 2003) . The level of expression of these immediate early genes is reflective of the spinal activation by the nociceptive input and is used therefore as an indirect marker of pain (Morgan and Curran, 1991) . As expected, BotAF attenuates in a dose-dependent manner the induction of pain-related expression of both c-fos and c-jun. These observations were previously also reported for other analgesic scorpion toxins (Bai et al., 2007; Liu et al., 2008; Martin-Eauclaire et al., 2010) . Also, the amount of Fos/Jun mRNA expression inhibition is correlated with the potency of analgesia. Several studies have shown that analgesics, given preemptively, reduce the extent of Fos expression in a dose-dependent manner with a good correlation with their potency . Hence, Finally, several experiments have been performed to identify or rule out some specific molecular pharmacological targets of BotAF. We investigated some of the proposed targets of BotAF structural toxin analogues that were described to possess analgesic activity: beta like scorpion toxins and depressant insect toxins (Guan et al., 2001) . Pharmacological targets of the b-like scorpion toxin family include TTX-resistant and TTX-sensitive voltage-gated Na þ channels (Chen et al., 2006; Zhu et al., 2009) . Apart from Na þ channels, the group of Ji (Tan et al., 2001) showed that BmKAS1 inhibits [ 3 H]-ryanodine binding on skeletal muscle by an indirect mechanism. Although Na þ channels constitute more relevant pharmacological targets for analgesic activity than ryanodine receptors, it should be stressed out that b-like scorpion toxins have weak affinities for Na þ channels. In fact, in brain synaptosomes, BotAF binds onto a weak affinity target, which is coherent with its lack of i.c.v. toxicity. We have also detected a limited activity of BotAF towards voltage-gated Na þ channels of DRG neurons and no activity at all onto ryanodine receptors. A more profound block of TTX-resistant Na þ channels was found suggesting that among the various members of voltagegated Na þ channels, BotAF may preferentially target TTX-resistant Na þ channels, although these findings are not very conclusive for the moment. It should be noted that the DRG neuron TTX-R sodium channels has been demonstrated to be the most promising targets for analgesics (Silos-Santiago, 2008) . Although our results are coherent with the effects of other members of the same family of toxins, the weak level of current inhibition and the relatively low affinity for this effect questions whether voltage-gated Na þ channels are the real pharmacological target whereby the potent analgesic effect of BotAF occurs. While several studies implicate ryanodine receptors in nociception, BotAF obviously lacks the ability to bind to ryanodine receptors contrary to the homologous toxins, BmKAS and AS1. For the depressant insect toxins group, another mechanism of anti-nociception was proposed: release of endogenous opioids. This is also not the case of BotAF where naloxone fails to antagonize the analgesic activity of BotAF. Thus, we conclude that more detailed investigations are warranted to identify the real pharmacological targets of BotAF. With regard to the analgesic effects of BotAF, several features are worth discussion. First, BotAF is active on acute somatic pain (hotplate and tail-flick models), on inflammatory somatic pain (formalin test), and on inflammatory visceral pain (writhing test). This indicates that BotAF acts through molecular targets that play a key role in conduction and transmission of different nociceptive information rather than on pain transduction. Second, the mode of action of BotAF does not involve opioid receptors or an AINS-like mechanism, clearly distinguishing this molecule from these common classes of analgesics. Third, the observation that BotAF prevents the increase in c-jun or c-fos under various pain stimuli is indicative that BotAF prevents the electrical activity of nociceptive neuronal afferents. This observation is in line with the data suggesting that the anti-nociceptive effect of BotAF is not mediated by a supra-spinal effect. In that respect, it is informative that the anti-nociceptive efficacy of BotAF is reliant on the mode of administration. The i.c.v. route was not efficient for analgesia in all pain models used in this study. Conversely, i.t. injection of BotAF was the most efficient mode of administration, at least in the pain model tested (tail-flick model). The intraplantar injection revealed itself also very efficient for the formalin test. Similarly, the i.p. injection was found more potent for the writhing test than the other modes of administration. These data indicate that the peripheral action of BotAF is best when locally administered at the same compartment than where the nociception generates. Altogether, these observations argue in favor of a peripheral and/or spinal mechanism for BotAF activity. 
